Robert C. Whorf

Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Ronald B. Natale, Sumitra Thongprasert, F. Anthony Greco et al. · Journal of Clinical Oncology · 2011 · 296 citations

Medicine, Oncology, Pharmacology +9

Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma

John D. Hainsworth, David R. Spigel, Howard A. Burris et al. · Journal of Clinical Oncology · 2010 · 175 citations

Medicine, Oncology, Pharmacology +17

Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer

David R. Spigel, Howard A. Burris, F. Anthony Greco et al. · Journal of Clinical Oncology · 2011 · 160 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

E. Gabriela Chiorean, Daniel D. Von Hoff, Josep Tabernero et al. · British Journal of Cancer · 2016 · 90 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC)

Robert C. Whorf, John D. Hainsworth, David R. Spigel et al. · Journal of Clinical Oncology · 2008 · 73 citations

Medicine, Oncology, Pharmacotherapy +17